<DOC>
	<DOCNO>NCT00252720</DOCNO>
	<brief_summary>The primary objective determine whether candesartan , compare placebo reduces progression diabetic retinopathy normotensive , normoalbuminuric type 1 diabetic patient retinopathy . The secondary objective determine whether candesartan , compare placebo , reduce incidence clinically significant macular oedema ( CSME ) and/or proliferative diabetic retinopathy ( PDR ) beneficially influences rate change urinary albumin excretion rate ( UAER ) . This study part DIRECT Programme also include primary prevention study diabetic retinopathy type 1 diabetes secondary prevention study type 2 diabetes . The primary objective three pooled study determine whether candesartan , compare placebo , reduce incidence microalbuminuria type 1 type 2 diabetic patient .</brief_summary>
	<brief_title>DIabetic Retinopathy Candesartan Trials .</brief_title>
	<detailed_description />
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<criteria>Male female age 18 55 year type 1 diabetes diagnose age 36 year need continuous insulin treatment within 1 year diagnosis diabetes include . Duration diabetes &gt; 1 year &lt; 20 year stable diabetic therapy within last 6 month . Patients untreated rest mean sit SBP &lt; 130 mmHg , mean sit DBP &lt; 85 mmHg retinal photograph grade level &gt; 20/10 &lt; 47/47 ( ETDRS severity scale ) . Patients follow condition exclude participation study : Cataract medium opacity degree precludes take gradable retinal photograph Angle closure glaucoma , preclude pharmacological dilatation pupil History presence proliferative retinopathy History presence clinical significant macular oedema ( CSME ) History evidence photocoagulation retina Other retinal condition may mask assessment , eg , retinal vein occlusion Positive micral dipstick test Presence secondary diabetes Pregnant lactate woman woman child bear potential practicing adequate method contraception Need treatment ACEinhibitor Haemodynamically significant aortic mitral valve stenosis Known renal artery stenosis kidney transplantation Hypersensitivity study drug Severe concomitant disease may interfere assessment patient , eg , malignancy , judge investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Diabetes mellitus type 1</keyword>
</DOC>